Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/26/2008

,000 54,223 127,633 178,869

Loss from operations (16,981) (9,369) (43,424) (57,288)

Equity in the income

of BioMarin/Genzyme

LLC 5,670 9,366 19,274 30,525

Interest income 3,951 7,383 12,417 25,932

Interest expense (2,957) (4,080) (13,411) (14,243)

Debt conversion

expense -- -- (3,315) --

Income (loss) before

income taxes (10,317) 3,300 (28,459) (15,074)

Provision for income

taxes 74 729 74 729

Net income (loss) $(10,391) $2,571 $(28,533) $(15,803)

Net income (loss)

per share, basic $(0.11) $0.03 $(0.34) $(0.16)

Net income (loss)

per share, diluted $(0.11) $0.03 $(0.34) $(0.16)

Shares used in per

share calculation

-- basic 91,552 96,931 84,582 95,878

Shares used in per

share calculation

-- diluted 91,552 101,193 84,582 95,878

(1) The following is the stock-based compensation expense included in the

respective captions of the consolidated statements of operations

above:

Three Months Ended Year Ended

December 31, December 31,

2006 2007 2006 2007

Stock-based compensation

expense:

Cost of goods sold $-- $162 $-- $578

Research and development 1,364 2,211 4,242 6,978

Selling, general and

administrative 1,727 3,092 5,348 10,727

Total
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, ... G.K. Butterfield (D-NC) took a bold bipartisan ... by introducing the OPEN Act. Original co-sponsors of ... (D-FL). The Act will incentivize drug makers and ... rare diseases and pediatric cancers, which opens the ...
(Date:11/24/2014)...   First published articles now ... Elsevier , a world-leading provider of scientific, technical and medical ... of the latest title in the Current Opinion journal ... . Current Opinion in ... to keep up-to-date with the expanding volume of information published ...
(Date:11/24/2014)... USA (PRWEB) November 23, 2014 One of ... field of optics and photonics is now available to high ... very low cost. SPIE, the international society for optics ... to the complete SPIE Digital Library available to ... price. , “Light-based technologies are integral to all areas of ...
Breaking Biology Technology:IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2
... not your parents' generation of corporate leaders. , ,A ... cross the lips of gray-haired, gray-suited corporate executives. Today, ... Wisconsin doesn't yet have it. , ,At the Olympia ... academic and arts groups met to brainstorm strategies for ...
... Wis. - The 53 Wisconsin companies that won ... Innovation Research (SBIR) and Small Business Technology Transfer (STTR) ... at an upcoming banquet in Madison. , ,The awards ... transfer workshop. The workshop will focus on SBIR/STTR funding ...
... 30 years ago, then-Gov. Pat Lucey and the Wisconsin ... property taxes. It was a bipartisan decision that has ... times and foreign competition threatened. , ,Today, Wisconsin policymakers ... a competitive toehold by reducing state taxes that discourage ...
Cached Biology Technology:Tech leaders call for more creativity 2Modernizing the tax code can make Wisconsin tech businesses more competitive 2Modernizing the tax code can make Wisconsin tech businesses more competitive 3
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
(Date:11/6/2014)... for a predator. Except when that predator runs so fast ... to its size, is the fastest creature on Earth. Some ... second (at about five miles per hour). The fastest human ... gold from the tiger beetle, a person would have to ... has a problem. At peak speeds, everything becomes a blur. ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... cells that promotes growth appears to spur restoration of ... sclerosis (MS), researchers at Case Western Reserve University School ... until published in the online version of Nature ... on Sunday, May 20. In animals injected with ...
... , , , , ... AUDIO: Plants capable of producing oils for industrial chemicals and human ... Click here for more information. , , ... , , , , , ...
... researchers from UCSF and UC San Diego has identified an ... and animal studies, suggesting it could offer a low-dose, low ... throughout the world. Based on these results, the ... as auranofin, from the U.S. Food and Drug Administration, and ...
Cached Biology News:Growth factor in stem cells may spur recovery from MS 2Supercharged safflower 2Supercharged safflower 3Supercharged safflower 4Lab tests show arthritis drug effective against global parasite 2Lab tests show arthritis drug effective against global parasite 3Lab tests show arthritis drug effective against global parasite 4
... stretching or compression of a single cell ... so you can precisely regulate the degree ... 64 unique strain parameters. ST-160 has a ... models are compatible with Nikon, Olympus, Leica, ...
... Glycosylation is a post-translational modification ... biological functions, including immune regulation, inflammation, ... Biotechnology has developed two lectin based ... and Wheat Germ Agglutinin (WGA), that ...
... Pierce offers maleimide activated carrier ... hapten-carrier conjugates. Imject Maleimide Activated Carrier ... have been preactivated with a heterobifunctional ... a stable, sulfhydryl-reactive carrier protein. ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: